Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 21;146(4):1157-1162.
doi: 10.1039/d0an01769h. Epub 2021 Jan 11.

Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population

Affiliations

Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population

Graeme F Murray et al. Analyst. .

Abstract

Adaptive resistance is a major limitation in the use of targeted therapies for cancer. Using real time biomass tracking, we demonstrate the isolation and identification of rare (1% fraction) diffuse large B cell lymphoma cells resistant to the PI3K inhibitor idelalisib, from an otherwise sensitive population. This technique allows direct study of these rare, drug tolerant cells.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1. (a) Schema of HSLCI. (1) Wide field phase detection camera, (2) illumination source, (3) micropipette system, (4) tubes for cell collection. (5) Dynamic focus control (b) examples of drug-tolerant and -sensitive DLBCL cells present in same culture. Left shows cell mass vs. time. Right shows HSLCI cellular mass density images of the two cells. Scale bars 10 μm.
Fig. 2
Fig. 2. (a & b) Representative box-plots of SU-DHL-6 and SU-DHL-10 cells treated with idelalisib. Individual dots in the overlaying box plot represent the mass accumulation rates of single cells measured over the interval 24–36 h post-dosing. The carrot “^” indicates the maximum dose reached in the blood of human patients given the prescribed dose. (c & d) The EC50 is calculated by sigmoidal fit to the median mass accumulation rates for SU-DHL-6 (N = 3) and SU-DHL-10 (N = 4). These responses indicate SU-DHL-6 is sensitive and SU-DHL-10 is resistant to idelalisib.
Fig. 3
Fig. 3. (a) Representative example (n = 3) of the isolation of the top 1% of growing cells from 1 : 100 SU-DHL-10/SU-DHL-6 mixture. Cells were treated with 2.5 μM idelalisib for 24 hours and mass accumulation rates were measured from 24–40 hours post dosing at which point the top 1% of growing cells were isolated by micropipette. (b) Cells isolated in (a) were cultured for 20 days then rescreened at 2.5 μM idelalisib. The median growth rate at 2.5 μM idelalisib increased from −0.2% ± 0.02% per hour in the isolation to 4.1% ± 0.12% per hour after re-culture. (c). In an experiment identical to (a), cells in the bottom <95th percentiles were isolated and cultured but no growth occurred. (d) PCR at the IGH-BCL2 loci for the cell line-specific breakpoints was performed on cells from stock SU-DHL-6 and -10 lines, and re-cultured cells indicating SU-DHL-10 cells were isolated from the 1 : 100 mixture.

Similar articles

Cited by

References

    1. Boumahdi S. de Sauvage F. J. Nat. Rev. Drug Discovery. 2020;19:39–56. doi: 10.1038/s41573-019-0044-1. - DOI - PubMed
    1. Beckman R. A. Loeb L. A. Clin. Pharmacol. Ther. 2020;108:437–439. doi: 10.1002/cpt.1938. - DOI - PMC - PubMed
    1. Hata A. N. Niederst M. J. Archibald H. L. Gomez-Caraballo M. Siddiqui F. M. Mulvey H. E. Maruvka Y. E. Ji F. Bhang H.-E. C. Krishnamurthy Radhakrishna V. Siravegna G. Hu H. Raoof S. Lockerman E. Kalsy A. Lee D. Keating C. L. Ruddy D. A. Damon L. J. Crystal A. S. Costa C. Piotrowska Z. Bardelli A. Iafrate A. J. Sadreyev R. I. Stegmeier F. Getz G. Sequist L. V. Faber A. C. Engelman J. A. Nat. Med. 2016;22:262–269. doi: 10.1038/nm.4040. - DOI - PMC - PubMed
    1. Song K.-A. Hosono Y. Turner C. Jacob S. Lochmann T. L. Murakami Y. Patel N. U. Ham J. Hu B. Powell K. M. Coon C. M. Windle B. E. Oya Y. Koblinski J. E. Harada H. Leverson J. D. Souers A. J. Hata A. N. Boikos S. Yatabe Y. Ebi H. Faber A. C. Clin. Cancer Res. 2018;24:5658. doi: 10.1158/1078-0432.CCR-18-0304. - DOI - PubMed
    1. Hangauer M. J. Viswanathan V. S. Ryan M. J. Bole D. Eaton J. K. Matov A. Galeas J. Dhruv H. D. Berens M. E. Schreiber S. L. McCormick F. McManus M. T. Nature. 2017;551:247–250. doi: 10.1038/nature24297. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources